ArticleResearch and practice in thrombosis and haemostasis2026
Platelet FcγRIIA is dispensable for hemostasis and arterial thrombosis in the absence of FcγRIIA-specific extracellular stimuli.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: FcγRIIA, a high-affinity receptor for immunoglobulin G immune complexes with no ortholog in mice, has a prominent role in host defense against pathogens via immune cell activation. A role for platelet FcγRIIA in enhancing thrombosis was suggested, involving interplay between α Objectives: This study assessed contribution of FcγRIIA to platelet function and experimental hemostasis and thrombosis without FcγRIIA-specific trigger. Methods: The role of FcγRIIA in platelet functions was evaluated using washed human platelets following blockade of FcγRIIA with the monoclonal antibody IV.3, and transgenic mice expressing human FcγRIIA (FcγRIIA Results: Aggregation of washed human platelets to various agonists was identical in the absence or presence of IV.3, as was aggregation of washed WT and FcγRIIA Conclusion: FcγRIIA does not contribute to platelet functions during hemostasis and arterial thrombosis in the absence of FcγRIIA-specific extracellular stimulation, which does not support a role for FcγRIIA in amplifying outside-in α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.